secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2021-12-13T23:59:59+00:00
Accession:  0001193125-21-354690
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir announces positive preliminary Phase 2 data for posoleucel in virus prevention in high-risk allo-HCT patients
--------------------------------------------------------------------------------

- No end-organ viral disease observed in 23 high-risk allo-HCT patients receiving posoleucel.
- Only 3 of 138 possible clinically significant infections occurred; 11 of 13 patients through Week 14 free of infection.
- FDA agreed in principle to advance to Phase 3 registrational trial expected to start in 1H 2022.
- Posoleucel targeting six viruses: AdV, BKV, CMV, EBV, HHV-6, and JCV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312521354690/0001193125-21-354690-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312521354690/d261161d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-354690

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer